A xanthone derivative MGS-3, confers protection against Staphylococcus aureus infection through SarA-mediated inhibition of alpha-hemolysin expression.
The global spread of methicillin-resistant Staphylococcus aureus (MRSA) underscores the urgent need for novel therapeutics. This study explores the anti-hemolytic activity and mechanism of MGS-3, a semi-synthetic xanthone derivative with potent anti-MRSA properties. Using a multi-tiered approach, we evaluated MGS-3's suppression of S. aureus α-hemolysin (Hla) through in vitro and in vivo models. Mechanistic studies combining gene editing, microscale thermophoresis (MST), and cellular thermal shift assays (CETSA) revealed that MGS-3 directly targets SarA, a key transcriptional regulator of hemolysin biosynthesis. MGS-3 exhibited dose-dependent inhibition of Hla virulence in strains ATCC29213, USA300, and NCTC8325 by repressing hla transcription and expression. Specifically, it downregulated sarA without affecting agrA, disrupting SarA's binding to the hla promoter and thereby reducing Hla-mediated cytotoxicity in A549 and A375 cells. In vivo, MGS-3 reduced skin abscess bacterial loads by 2.1-fold, comparable to ΔsarA (2.3-fold), while mitigating cytokine response and improving histopathology. These results establish SarA suppression as MGS-3's primary anti-virulence mechanism. Notably, MGS-3 maintained low hemolytic activity, highlighting its therapeutic potential. MGS-3 represents a promising candidate for anti-staphylococcal drug development, targeting virulence rather than bacterial viability to potentially curb resistance evolution. This study provides a pharmacodynamic foundation for novel anti-MRSA strategies. IMPORTANCE: The global spread of methicillin-resistant Staphylococcus aureus(MRSA) requires new treatments. The semi-synthetic xanthone derivative MGS-3 inhibits α-hemolysin production by targeting the SarA regulator, reducing virulence. In a murine skin abscess model, it significantly lowered bacterial load and mitigated inflammation. This anti-virulence strategy presents a promising approach to combat MRSA.